[(2R,3R,4S,5S)-3,4-Dihydroxy-5-(4-oxo-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-7-yl)-2-pyrrolidinyl]methyl dihydrogen phosphate
Star0
Identification
- Generic Name
- [(2R,3R,4S,5S)-3,4-Dihydroxy-5-(4-oxo-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-7-yl)-2-pyrrolidinyl]methyl dihydrogen phosphate
- DrugBank Accession Number
- DB02075
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 346.2332
Monoisotopic: 346.067835366 - Chemical Formula
- C11H15N4O7P
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UHypoxanthine-guanine-xanthine phosphoribosyltransferase Not Available Plasmodium falciparum (isolate FCR-3 / Gambia) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyrrolopyrimidines. These are compounds containing a pyrrolopyrimidine moiety, which consists of a pyrrole ring fused to a pyrimidine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyrrolopyrimidines
- Sub Class
- Not Available
- Direct Parent
- Pyrrolopyrimidines
- Alternative Parents
- Pyrimidones / Monoalkyl phosphates / Aralkylamines / Substituted pyrroles / Vinylogous amides / Pyrrolidines / Heteroaromatic compounds / Secondary alcohols / 1,2-diols / 1,2-aminoalcohols show 5 more
- Substituents
- 1,2-aminoalcohol / 1,2-diol / Alcohol / Alkyl phosphate / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Heteroaromatic compound / Hydrocarbon derivative show 19 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- ribitol phosphate, dihydroxypyrrolidine, pyrrolopyrimidine (CHEBI:43395)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- VJTAXXUIRYOXBT-KUBHLMPHSA-N
- InChI
- InChI=1S/C11H15N4O7P/c16-9-5(2-22-23(19,20)21)15-7(10(9)17)4-1-12-8-6(4)13-3-14-11(8)18/h1,3,5,7,9-10,12,15-17H,2H2,(H,13,14,18)(H2,19,20,21)/t5-,7+,9-,10+/m1/s1
- IUPAC Name
- {[(2R,3R,4S,5S)-3,4-dihydroxy-5-{4-oxo-1H,4H,5H-pyrrolo[3,2-d]pyrimidin-7-yl}pyrrolidin-2-yl]methoxy}phosphonic acid
- SMILES
- [H]N1C=C([C@@H]2N([H])[C@H](COP(O)(O)=O)[C@@H](O)[C@H]2O)C2=C1C(=O)N=CN2[H]
References
- General References
- Not Available
- External Links
- PubChem Compound
- 444833
- PubChem Substance
- 46507599
- ChemSpider
- 392646
- ZINC
- ZINC000015479974
- PDBe Ligand
- IRP
- PDB Entries
- 1cjb / 8fx2
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 3.77 mg/mL ALOGPS logP -1.3 ALOGPS logP -3.5 Chemaxon logS -2 ALOGPS pKa (Strongest Acidic) 1.5 Chemaxon pKa (Strongest Basic) 8.62 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 9 Chemaxon Hydrogen Donor Count 7 Chemaxon Polar Surface Area 176.5 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 76.81 m3·mol-1 Chemaxon Polarizability 29.26 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.6272 Blood Brain Barrier - 0.6851 Caco-2 permeable - 0.733 P-glycoprotein substrate Substrate 0.5246 P-glycoprotein inhibitor I Non-inhibitor 0.9428 P-glycoprotein inhibitor II Non-inhibitor 0.9709 Renal organic cation transporter Non-inhibitor 0.9286 CYP450 2C9 substrate Non-substrate 0.7786 CYP450 2D6 substrate Non-substrate 0.8141 CYP450 3A4 substrate Non-substrate 0.5239 CYP450 1A2 substrate Non-inhibitor 0.8235 CYP450 2C9 inhibitor Non-inhibitor 0.8997 CYP450 2D6 inhibitor Non-inhibitor 0.8794 CYP450 2C19 inhibitor Non-inhibitor 0.8915 CYP450 3A4 inhibitor Non-inhibitor 0.8687 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9252 Ames test Non AMES toxic 0.7568 Carcinogenicity Non-carcinogens 0.8876 Biodegradation Not ready biodegradable 0.9194 Rat acute toxicity 2.3575 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9801 hERG inhibition (predictor II) Non-inhibitor 0.8225
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-0091000000-cc01ac142f0e4c4117c2 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004j-9003000000-aec074e706cca1e14497 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-001s-0490000000-ab0bcc8be687c1f2cbea Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9000000000-9bbc041a48805948beff Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-000b-0950000000-bd2cb3fca007618b6c49 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9000000000-5b9c2629eda64da62458 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 160.68983 predictedDeepCCS 1.0 (2019) [M+H]+ 163.08542 predictedDeepCCS 1.0 (2019) [M+Na]+ 168.99794 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Plasmodium falciparum (isolate FCR-3 / Gambia)
- Pharmacological action
- Unknown
- General Function
- Xanthine phosphoribosyltransferase activity
- Specific Function
- Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5-phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. Works with guanine, ...
- Gene Name
- LACZ
- Uniprot ID
- P20035
- Uniprot Name
- Hypoxanthine-guanine-xanthine phosphoribosyltransferase
- Molecular Weight
- 26348.18 Da
References
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52